Mutual of America Capital Management LLC Sells 3,535 Shares of Edwards Lifesciences Co. (NYSE:EW)

Mutual of America Capital Management LLC cut its position in Edwards Lifesciences Co. (NYSE:EW) by 4.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,811 shares of the medical research company’s stock after selling 3,535 shares during the period. Mutual of America Capital Management LLC’s holdings in Edwards Lifesciences were worth $5,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP grew its stake in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after acquiring an additional 14,610,123 shares in the last quarter. State Street Corp lifted its holdings in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after acquiring an additional 256,538 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after acquiring an additional 284,918 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 9.8% in the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at about $555,939,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Canaccord Genuity Group lifted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a report on Thursday, February 13th. Barclays lifted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. The Goldman Sachs Group lifted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, December 5th. Finally, Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $82.00 to $90.00 in a research report on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Down 0.3 %

NYSE EW opened at $71.37 on Tuesday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market cap of $42.09 billion, a PE ratio of 10.24, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10. The company has a 50 day moving average price of $72.58 and a 200 day moving average price of $70.32. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $70.78, for a total transaction of $796,275.00. Following the completion of the sale, the chief financial officer now directly owns 30,387 shares in the company, valued at $2,150,791.86. This trade represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,739 shares of company stock worth $2,799,104. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.